All articles tagged with #genmab
Denmark's Genmab is acquiring Dutch biotech Merus for approximately $8 billion in a deal that includes a 41% premium over Merus' recent stock price, aiming to expand its pipeline in cancer treatments through this strategic acquisition funded by cash and debt.,
Genmab has announced the acquisition of ProfoundBio for USD 1.8 billion in cash, giving Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), and ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms. This acquisition will broaden Genmab’s mid- to late-stage clinical pipeline and strengthen its suite of proprietary technology platforms, potentially creating new opportunities to develop cancer medicines. The addition of Rina-S to Genmab’s portfolio aims to deepen its presence in gynecologic oncology and establish a firm foundation in solid tumors, with the potential to transform the treatment of cancer and improve patient lives.
The FDA has approved AbbVie and Genmab's blood cancer therapy, Epkinly, for adult patients who have received at least two prior lines of treatment. The therapy treats a type of advanced large B-cell lymphoma and is the first-of-its-kind to be approved by the FDA for the disease. The list price of Epkinly is $37,500 per month, and it is expected to reach $2.75 billion in peak sales globally. The therapy is being co-developed by AbbVie and Genmab as part of a $750 million deal made in 2020 to jointly develop and commercialize three of Genmab's cancer-targeting antibody products.
Genmab, a Danish antibody specialist with a $27 billion market cap, has announced a multi-year research deal with Dutch drugmaker argenx to enter the immunology and inflammation market. The companies will split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time. Genmab CEO Jan van de Winkel touts M&A potential as the company expands beyond oncology.